Introduction: The Dual Reality of Advocacy and Personal Struggle
In the world of metastatic breast cancer (MBC) advocacy, the lines between personal experience and professional commitment are often blurred. For Dr. Kelly Shanahan, M.D., president of METAvivor, the dual burden of leading a premier patient-advocacy organization while navigating the shifting landscape of her own stage IV diagnosis is a testament to the urgency of the cause.
In her latest communication, Dr. Shanahan shares a candid update on the state of the organization, the necessity of biomarker testing, and the personal reality of treatment recalibration. As summer transitions into fall, her message serves as a reminder that for those living with MBC, time is a commodity measured not just in months, but in the precision of clinical responses and the evolution of tumor mutations.
The Reality of Progression: A Personal Clinical Update
Dr. Shanahan’s summer was defined by two distinct challenges: a physical injury caused by her energetic eight-month-old puppy, Albus Dumbledore, and a significant medical pivot. Her previous clinical trial, which initially offered promise, eventually faltered.
"The spots that showed initial response were still responding," Dr. Shanahan noted, "but my highly ER/PR+ MBC has decided to mutate to low ER/PR-, HER2 low, and move to my liver."
This transition is a hallmark of the volatile nature of metastatic disease. Upon consultation with her "village of oncologists," she shifted her therapeutic approach to include immunotherapy—driven by a high tumor mutational burden identified via liquid biopsy—and oral chemotherapy with capecitabine (Xeloda). Early signs, such as the resolution of numbness in a site previously affected by a new metastasis, offer cautious optimism. However, as is standard practice for those in the MBC community, the true efficacy of this new regimen will not be confirmed until upcoming scans in late August.
Biomarker Education: Why Molecular Precision Matters
One of the central pillars of Dr. Shanahan’s tenure at METAvivor is the aggressive push for biomarker education. When a patient experiences "mixed response"—where some lesions respond to treatment while others progress—the biological profile of the cancer may be shifting.
The Importance of Biopsies and Liquid Diagnostics
Dr. Shanahan emphasizes that when treatment protocols change, the diagnostic approach must follow suit. "It is so important when we have a mixed response to treatment that we get biopsies of the new spots if at all possible," she writes.
Furthermore, she advocates for the routine use of liquid biopsies. These blood-based tests are critical in identifying mutations in real-time, allowing clinicians to pivot treatment strategies before a patient faces catastrophic progression. To operationalize this, METAvivor is launching a comprehensive biomarker education program. This initiative will integrate web-based resources, social media outreach, and a specialized panel at the upcoming Stage IV Stampede and Summit, scheduled for October 5 in Washington, D.C.
Strengthening the Ecosystem: Advocacy and Collaboration
METAvivor is expanding its reach through strategic partnerships designed to amplify the voices of patients and researchers alike.
The ‘Live from Stage 4’ Partnership
A significant development is the new partnership with the Live from Stage 4 podcast. This collaboration aims to provide a platform for:
- Clinical Insights: Interviews with leading oncologists and researchers regarding the latest breakthroughs in MBC treatment.
- Patient Narratives: Panels featuring individuals living with MBC who discuss their lived experiences, including the management of treatment-related side effects.
- Institutional Integration: Future segments will feature METAvivor-funded researchers and highlight key programs, such as peer-to-peer support networks and the newly minted R.I.S.E. (Reach. Inform. Support. Empower) initiative.
Chronology of Upcoming Advocacy Milestones
The advocacy calendar for the final quarter of the year is packed with events designed to influence policy and foster community.
- October 5: Stage IV Stampede and Summit. This event precedes Hill Day, bringing advocates directly to the seat of government to demand increased research funding and policy changes.
- October 6: Hill Day. Advocates will engage with lawmakers to emphasize the urgent need for metastatic-specific research.
- October 13: Light Up MBC. This is the organization’s marquee annual fundraiser, a global event that illuminates landmarks and communities to raise awareness and critical funds.
- Late Fall: A specialized webinar series focusing on the complexities of managing multiple biomarkers, providing patients with the knowledge to navigate the nuances of personalized medicine.
Empowering the Patient-Advocate
At the heart of METAvivor’s success is its grant process, which is uniquely shaped by the input of those who understand the disease best: the patients. Dr. Shanahan confirmed that patient advocate reviewers are currently being assigned grant applications to evaluate.
"Your thoughtful input is vital to our grant process," she noted. By involving patients in the review of scientific proposals, METAvivor ensures that the research it funds aligns with the most pressing needs and quality-of-life concerns of the MBC community. Those interested in participating in the 2025 review cycle are encouraged to register through the organization’s online portal.
Implications: The Future of METAvivor
The message from Dr. Shanahan is one of resilience. METAvivor exists as a direct reflection of the needs of the MBC community. As the organization looks toward the end of the year, its focus remains threefold: scientific discovery, legislative advocacy, and community support.
Sustaining the Mission
For those looking to engage, the opportunities are vast. Whether through fundraising, volunteering, or contributing to new initiatives, the organization relies on the active participation of its community. The success of the Light Up MBC campaign, led by Tami Bowling and her team, remains critical to maintaining the research pipeline that METAvivor supports.
A Final Reflection
Dr. Shanahan’s update highlights the fragility of life with MBC, but also the strength found in collective action. Her personal journey—from a simple foot injury to a complex mutation in her disease—serves as a microcosmic look at the challenges faced by thousands of patients.
By demanding better diagnostics (biomarkers), fostering education (webinars and summits), and partnering with media platforms to spread awareness, METAvivor is not just providing support; it is fundamentally altering the landscape of metastatic breast cancer treatment.
As she continues her own battle, her leadership remains a guiding light. The message is clear: while the disease is unpredictable, the commitment of the advocacy community is steadfast. The upcoming fall season, with its legislative summits and awareness campaigns, represents a pivotal moment for those fighting for a future where metastatic breast cancer is no longer a terminal diagnosis.
Supporting Data and Organizational Context
The Scientific Mandate
The shift toward precision oncology is no longer optional for MBC patients. Research indicates that approximately 30-50% of metastatic breast cancers exhibit some form of clonal evolution or change in receptor status (ER/PR/HER2) during the course of the disease. Dr. Shanahan’s experience underscores why re-biopsy of metastatic sites is the gold standard of care.
The Role of METAvivor
METAvivor is unique in that 100% of its donations go toward funding research for metastatic breast cancer. By facilitating a direct link between the research community and the patient population, the organization ensures that funding is allocated to projects with the highest potential for immediate clinical impact.
The launch of the R.I.S.E. initiative marks a shift toward more holistic patient support, recognizing that the emotional and practical toll of a stage IV diagnosis requires resources beyond just clinical medicine.
Moving Forward
As the community prepares for the October events, the focus remains on "moving the needle." For Dr. Shanahan, every day is a combination of professional duty and the personal navigation of a new treatment path. Her resilience is not just a personal trait—it is the driving force behind one of the most effective patient advocacy organizations in the United States today.
"METAvivor exists for and because of you," she concludes. For patients and caregivers alike, that sentiment is the bedrock upon which the hope for a cure is built.
About the Author
